Doxazosin Mesylate
Product Images NDC 53808-1107

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Doxazosin Mesylate (NDC 53808-1107). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image For 4mg (Doxazosin Mesylate 4mg)

Label for Doxazosin Mesylate 4 mg tablets showing a quantity of 30 tablets. It is prescription only and manufactured by Patheon, with an expiration date of 12-14-18. The product is packaged by DOH Central Pharmacy located in Tallahassee, FL 32304. UPC code 006042995519 is also visible.*

FDA Label Image

Image Of The Chemical Structure Of Doxazosin Mesylate. (Doxazosin 1)

Chemical structure of doxazosin mesylate showing the molecular arrangement including aromatic rings, nitrogen atoms within heterocyclic rings, methoxy groups, and the mesylate component.*

FDA Label Image

Table 3 Summary Of Effectiveness Data In Placebo-controlled Trials (Doxazosin 2)

Table 3 presents a summary of effectiveness data in placebo-controlled trials for Doxazosin Mesylate versus placebo. It compares symptom scores and maximum flow rate (mL/sec) across three studies with different dosing regimens, showing mean baseline values and mean changes. A bar graph illustrates maximum flow rate changes for placebo, 4 mg, and 8 mg doses in Study 2, accompanied by study footnotes explaining scoring questionnaires and statistical significance.*

FDA Label Image

Image Of Figure 1-study 1 (Doxazosin 3)

A line graph titled 'Figure 1-Study 1' showing mean change in total symptom score from baseline over a 14-week treatment duration. Two lines compare placebo (N=47) and doxazosin mesylate (N=50), with doxazosin mesylate demonstrating a greater mean symptom score reduction over time. Error bars indicate variability at each time point.*

FDA Label Image

Image Of Figure 1-study 1 (Doxazosin 4)

A line graph showing the mean increase in maximum urinary flow rate (mL/sec) over a 14-week treatment duration comparing doxazosin mesylate and placebo. The doxazosin mesylate group shows a generally higher increase in flow rate than placebo, with data points marked for statistical significance. Sample sizes are N=50 for doxazosin mesylate and N=47 for placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.